Develop Next-Generation HIV Therapies A high priority of NIH-sponsored research is to develop next-generation HIV therapies. Despite the advent of simplified daily combination treatments which provide sustained viral suppression, there is still a need to identify new long-acting medications with fewer side effects in parallel with the development of novel delivery and testing technologies to improve efficacy of and adherence to treatment. To achieve this goal, ERC-CFAR investigators are applying basic sciences research and drug discovery strategies to identify new druggable targets that prevent viral assembly or virus-host interactions, develop new preclinical drug animal models and develop broadly neutralizing antibodies as a new sustained anti-HIV treatment. Listed below are NIH-funded studies by our ERC-CFAR Investigators researching strategies to develop Next-Generation HIV therapies. Investigator Institution NIH Grant Title Paul Bieniasz Rockefeller R01AI157809 Host protein targets of HIV-1 vpr in gene expression, cell cycle and innate immunity Paul Bieniasz Rockefeller R01AI050111 RNA protein interactions in HIV-1 replication Paul Bieniasz. Rockefeller R37AI064003 Discovery and mechanism of antiretroviral factors Felipe Diaz-Griffero Einstein R01AI087390 Modulation of retroviral uncoating by cellular factors Felipe Diaz-Griffero Einstein R01AI150455 Regulation of SAMHD1 antiviral activity Harris Goldstein Einstein R01AI145024 Novel biologics designed to mobilize HIV-specific CTL for sustained HIV remission Ganjam Kalpana Einstein R21AI156932 Structure-based design of stapled peptides to target Gag-Pol and INI1 interaction to block assembly Denis Nash CUNY SPH R34MH126809 Assessing Perceptions and Preferences around Long-acting Injectables (APPLI) in the Ryan White HIV/AIDS Program
